Combination Treatment for HIV

April 2004
Combination Treatment for HIV;4/1/2004, p1
The article presents information about combination treatment for human immunodeficiency viruses (HIV). It enumerates the four main types of HIV drugs namely nucleoside analogues, non-nucleoside analogues, protease inhibitors and fusion inhibitors. It cites the side effects of combining these antiviral drugs such as rashes and headache. It also discusses how to take combination treatment.


Related Articles

  • New risk information added to label of antiviral saquinavir.  // AIDS Alert;Dec2010, Vol. 25 Issue 12, p143 

    The article reports that the U.S. Food and Drug Administration (FDA) is advising the public that another risk information has been included in the label of saquinavir (Invirase®), describing the possible change in the heart's electrical activity when the antiviral drug is administered, along...

  • World AIDS Day brings hope to those living with HIV/AIDS.  // Gay & Lesbian Times;11/25/2004, Issue 883, p12 

    Editorial. States that the World AIDS Day on December 1, 2004 will bring hope to people living with AIDS and HIV. AIDS Day's representation of progress in the treatment of AIDS, such as the development of AZT and combination drug therapy; Development of novel protease inhibitors that cause fewer...

  • indinavir.  // Royal Society of Medicine: Medicines;2002, p302 

    This article provides information on indinavir, an antiviral drug. It is often used together with antivirals. It can be used in the treatment of HIV infection. Administration of the drug is oral. It is a specialist drug, and there will be full assessment of patient suitability, with an...

  • Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy. Tran, Tu-Anh; Ghosn, Jade; Avettand-Fenoë, Véronique; Hendel-Chavez, Houria; de Goër de Herve, Marie-Ghislaine; Cohen-Codar, Isabelle; Rouzioux, Christine; Delfraissy, Jean-François; Taoufik, Yassine // Journal of Antimicrobial Chemotherapy (JAC);Sep2015, Vol. 70 Issue 9, p2627 

    Background: Antiretroviral combination therapy raises issues of long-term adherence and toxicity. Initial treatment simplification based on single-drug therapy was investigated in the MONARK trial, which compared first-line lopinavir/ritonavir monotherapy (arm A) with first-line...

  • Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection. Poordad, Fred; Sievert, William; Mollison, Lindsay; Bennett, Michael; Tse, Edmund; Bräu, Norbert; Levin, James; Sepe, Thomas; Lee, Samuel S.; Angus, Peter; Conway, Brian; Pol, Stanislas; Boyer, Nathalie; Bronowicki, Jean-Pierre; Jacobson, Ira; Muir, Andrew J.; Reddy, Rajender; Tam, Edward; Ortiz-Lasanta, Grisell; de Lédinghen, Victor // JAMA: Journal of the American Medical Association;5/5/2015, Vol. 313 Issue 17, p1728 

    IMPORTANCE The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. OBJECTIVE To determine the rates of sustained virologic response (SVR) in patients receiving the 3-drug combination of...

  • HIV Drugs Interfere With Blood Sugar, Lead to Insulin Resistance.  // Asian Journal of Biochemistry;2011, Vol. 6 Issue 3, p300 

    No abstract available.

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2000, Vol. 14 Issue 10, p567 

    Presents various medical news briefs related to side effects of antiviral drugs for HIV infections. Ability of protease inhibitors to cause sexual dysfunction; Role of highly active antiretroviral therapy in causing curly hair; Interaction between Viagra and ritonavir or saquinavir.

  • EFAVIRENZ POTENT IN ADULTS.  // AIDS Patient Care & STDs;Mar2000, Vol. 14 Issue 3, p170 

    Cites the findings of a DuPont 006 study regarding the use of efavirenz when compared to the protease inhibitor indinavir. Support for the use of efavirenz among HIV patients who are treatment-naive; Random assignments into possible treatment regimens.

  • Protease inhibitors may cause fat abnormalities and heart disease. Berger, Abi // BMJ: British Medical Journal (International Edition);07/11/98, Vol. 317 Issue 7151, p100 

    States that protease inhibitors are possible causes of the changes associated with body fat distribution and rising cholesterol concentration in persons infected with the human immunodeficiency virus (HIV). Description of the two protease inhibitors which are implicated in these metabolic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics